Can-Fite BioPharma Ltd.
AI Valuation
AI-generated fair value estimate for this company.
AI Fair Value
$2.65
Market Price
$2.10
Undervalued By
20.8%
Method: Explicit 10-year cash-flow model for a distressed clinical-stage biotech: modest cash flows of -$1M to $1.5M per year reflecting its small CANfite pipeline optionality; 18% discount rate; 1% terminal growth; -$7.0M net cash; 4.29M shares outstanding.
Reasoning: Can-Fite is a micro-cap clinical-stage biotech with a negative enterprise value (market cap below net cash), signaling the market assigns little value to its pipeline; I valued it close to net cash plus a small risk-adjusted pipeline component given its going-concern-adjacent financial position and minimal revenue.